From Name:
From Email:
To Name:
To Email:

Optional Message:


Paclitaxel prevails in ovarian cancer trials

from MedPage Today

Two alternatives to paclitaxel for recurrent ovarian cancer failed to slow disease progression in separate randomized trials. In one trial paclitaxel and cabozantinib (Cometriq) led to similar median progression-free survival (PFS) of 5 to 6 months. Analyses of overall survival, response to therapy, and event-free survival (EFS) suggested that patients treated with cabozantinib might have fared worse than their counterparts in the paclitaxel arm, Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute in Boston, reported here at the Society of Gynecologic Oncology Annual Meeting. more


Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063